Enlitic Inc · ASX:ENL
Enlitic — Investor Presentation (May 2025)
40 slides from Enlitic's investor presentation, May 5, 2025
Slide 1: Capital Raising May 2025
For personal use only Capital Raising May 2025 1 All Rights Reserved © Copyright, Enlitic, Inc. 2025
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER The following notice and disclaimer apply to this investor presentation (Presentation) and you are therefore advised to read this carefully The information in this Presentation does not take into account the particular investment objectives, financial situation, taxat
Slide 3: Important Notice and Disclaimer (cont)
IMPORTANT NOTICE AND DISCLAIMER (cont) Future performance and forward-looking statements Any pro forma financial information does not purport to be in compliance with Article 11 of Regulation S-X of the Rules of the U.S. Securities and Exchange Commission and has not been prepared with a view toward
Slide 4: Important Notice and Disclaimer (cont) - Key investment risks
IMPORTANT NOTICE AND DISCLAIMER (cont) Key investment risks There are a number of risks specific to the Equity Raising, Enlitic and of a general nature which may affect the future operating and financial For personal use only performance of Enlitic and the value of an investment in Enlitic, includin
Slide 5: Executive Summary
Executive Summary Enlitic is a software development company that uses artificial intelligence to develop software products that manage medical imaging data in radiology and licences such products to healthcare providers. Acquisition of Laitek has expanded the Enlitic portfolio to include data migrat
Slide 6: Business Overview
For personal use only Business Overview 6 © Copyright, Enlitic, Inc. 2025
Slide 7: Key Business Highlights
Key Business Highlights SIGNIFICANT COMMERCIAL PROGRESS • Migration pipeline1 grown by more than US$60m since Laitek acquisition. • Secured US$1.6m (A$2.6m) of new revenue in 1Q25 to date, with 75% expected to be recognized in CY2025. For personal use only GE HEALTHCARE COLLABORATION • Executed bind
Slide 8: Key Business Updates
Key Business Updates Increased market awareness has raised Material interest in combined Ensight and Migration Services offerings interest from both OEM and healthcare Active migration opportunities with PACS OEMs representing >60% of Global PACS market share. providers alike. For personal use only
Slide 9: Equity Raise Details
For personal use only Equity Raise Details 9 © Copyright, Enlitic, Inc. 2025
Slide 10: Placement Overview
Placement Overview Placement • Two-tranche placement seeking to raise $10.0 million via the issue of 250 million new chess depositary interests (New CDIs or Placement Securities) at the Offer Price to sophisticated and professional investors (Placement). o Tranche one will raise ~$5.8 million (~145.
Slide 11: Indicative Timetable
Indicative Timetable Indicative Timetable Date (AEST) Offeror Trading Halt Thursday 1 May 2025 For personal use only Trading Halt Lifted and Return to Trading on the ASX Monday 5 May 2025 Settlement of Tranche One Placement Securities Friday, 9 May 2025 Allotment of Tranche One Placement Securities
Slide 12: Use of Funds
Use of Funds Sources Commentary Placement A$10M • Research and Development: Further development of Enlitic’s Total Sources A$10M core technology platform and further development of our For personal use only migration technology • Quality and Regulatory: Maintain quality certification and regulatory
Slide 13: Pro Forma Capital Structure
Pro Forma Capital Structure PRO FORMA CAPITAL STRUCTURE1 Current common stock on issue 583.2 million For personal use only New CDIs issued under the Tranche One Placement 145.8 million New CDIs issued under the Tranche Two Placement2 104.2 million Total CDIs on issue post Placement2 833.2 million Ne
Slide 14: Business Overview
For personal use only Business Overview 14 © Copyright, Enlitic, Inc. 2025
Slide 15: Commercial Progress
Commercial Progress 1Q25 New business signed US$1.6m Expect to recognize >US$1.2m (A$2.0m) of this work For personal use only (A$2.7m) in CY2025. Costs reductions >US$2.0m Up to a further US$1.0m p.a. cost reductions P.A. cost synergies identified for the remainder of CY2025. achieved Commercial foc
Slide 16: Integration Progress: Revenue Synergies
Integration Progress Expected Revenue Synergies at Acquisition Data Migration Market Share Growth ENL Subscription Revenue For personal use only The combined service offering of Laitek and Enlitic will be a Enlitic intends to bundle its product when selling to Laitek’s ~US$5.0M point of differentiat
Slide 17: Integration Progress: Cost Synergies
Integration Progress Expected Cost Synergies at Acquisition Employee Right Sizing Duplication Costs For personal use only The combined employee base will be right sized in line with Certain duplicated internal costs are to be removed. ~US$1.0M p.a. other peers. (i.e. marketing, conferences , IT, tra
Slide 18: OEM Engagement
OEM Engagement Material interest in combined Ensight and Migration Services offering 2024 PACS Market Share 2024 PACS Market Share For personal use only Standardization Target OEM Migration Target OEM Intelerad Merative GEHC Intelerad Merative 8% GEHC Siemens 1% 15% Siemens 1% 8% 15% 10% 10% Canon H
Slide 19: Enlitic Combined Pipeline
Enlitic Combined Pipeline1 Accelerating Revenue Targets via Advancing Key Pipeline Opportunities For personal use only Pipeline Pipeline Stage No. of Contracts Total Contract Value • Pipeline remains healthy and growing Pending Progression2 37 $32.0m • Focus on conversion and implementation. ENSIGHT
Slide 20: GE HealthCare Relationship Formalized
GE HealthCare Relationship Formalized GEHC Genesis Portfolio GEHC announced a new cloud-suite of enterprise imaging Genesis Cloud For personal use only solutions at HIMSS 2025. Enterprise Imaging SaaS Solutions Vendor Neutral • Designed to improve patient care coordination, reduce Edge Archive opera
Slide 21: GE HealthCare Binding MOU Terms
GE HealthCare Binding MOU Terms1 US$6m (A$10m) For personal use only Additional Enlitic funding required GE arrangements conditional on Enlitic securing additional funding. US$2m (A$3.25m) Prepayment for Enlitic services GEHC to prepay for Migration Services. US$3-6m/yr Current Discussions (A$5-10m)
Slide 22: Financial Outlook
Financial Outlook Operational Cashflow Break-even Anticipated to achieve operational cashflow break-even for Year-End CY2025. For personal use only Recognized Revenue Anticipated 2025 Recognized Revenue of US$9-11m. GE HealthCare If base migration capacity secured by ENL and certain formal agreement
Slide 23: Appendix
For personal use only Appendix 23 © Copyright, Enlitic, Inc. 2025
Slide 24: Key Risks
For personal use only KEY RISKS 24 © Copyright, Enlitic, Inc. 2025
Slide 25: Key Risks
Key Risks This Appendix describes some (but not all) of the key risks associated with an investment in Enlitic, together with risks associated with Equity Raising. Enlitic is subject to a number of risks both specific to Enlitic’s business activities and of a general nature, which may, either indivi
Slide 26: Key Risks: Going concern risk
Key Risks Going concern risk As indicated by the Company’s Appendix 4C released 30 April 2025, the Company’s cash reserves as at 31 March 2025 were sufficient to fund 0.71 quarters. Therefore, existing funds will not be sufficient to meet the Company’s required expenditure beyond a 2-month period fr
Slide 27: Key Risks: Risks specific to Enlitic
Key Risks Risks specific to Enlitic Use of artificial intelligence in Enlitic’s product offering The Company’s product offering relies on the use of artificial intelligence (AI) in data management applications. The use of AI in Enlitic’s product offering can lead to potentially inaccurate or unrelia
Slide 28: Key Risks: Failure to realise benefits from R&D
Key Risks Failure to realise benefits from product research and development Developing software and technology is expensive and often involves an extended period of time prior to any return on investment (if at all). The continued investment in innovation and related product development opportunitie
Slide 29: Key Risks: Competition
Key Risks Competition Currently, Enlitic believes there are no competitors to Enlitic’s ENDEX product in the global healthcare IT market in the radiology sub-sector. However, with respect to Enlitic’s current or proposed offerings in relation to anonymisation, billing/coding and real-world evidence
Slide 30: Key Risks: Concentration of customers
Key Risks Concentration of customers Enlitic’s customer base currently consists of healthcare providers and distribution partners. Enlitic’s offering to any one of these customers can generate a large proportional amount of revenue, and accordingly, the financial performance of Enlitic is susceptibl
Slide 31: Key Risks: Breach of third party IP rights
Key Risks Breach of third party intellectual; property rights There is a risk that third parties may allege that Enlitic (or its products) has infringed their intellectual property rights. To the extent Enlitic gains greater market visibility, Enlitic faces a higher risk of being the subject of inte
Slide 32: Key Risks: Failures or disruptions in technology
Key Risks Failures or disruptions in technology The Company depends on the performance, reliability, and availability of its technology systems. Enlitic may in the future experience website and cloud service disruptions, storage failures, outages, and other performance problems related to these vend
Slide 33: Key Risks: General Risks
Key Risks General Risks General Investors should be aware that there are risks associated with any securities investment. The prices at which the Company’s CDIs trade may be above or below the offer price under the Placement, and may fluctuate in response to a number of factors, including those note
Slide 34: Key Risks: Exchange rate risks
Key Risks Exchange rate risks Additionally, the proceeds of the Equity Raising will be received in Australian dollars while Enlitic’s functional currency is U.S. dollars. Enlitic is not currently hedging against exchange rate fluctuations, and consequently it will be at the risk of any adverse movem
Slide 35: What We Do
What We Do The delivery of Ensight 2.0 lays the foundations for expanding capabilities ENLITIC CORE COMPETENCY For personal use only Illustrative Example STUDIES DATA Tangible Benefit Use Case Description Hanging Protocols Improve ENSIGHT 2.0 Radiologist Dictation template Puts time back in the hand
Slide 36: What We Do: Breaking down DICOM studies
What We Do Breaking down DICOM studies ENLITIC CORE COMPETENCY For personal use only Tangible Benefit Use Case Description Orders, Medical Images & Reports Hanging Protocols • 1000s of inconsistent data points across Improve 1 radiology orders, DICOM images, meta-data and reports. Radiologist Produc
Slide 37: Tech Enabled Data Migration
Tech Enabled Data Migration An essential component of the medical imaging ecosystem TECH ENABLED DATA MIGRATION For personal use only THE PREMISE IS SIMPLE THE REALITY: HIGHLY COMPLEX Many millions of studies encompassing petabytes of data are needed The process of extracting, translating and loadin
Slide 38: AI Enabled Data Migration
AI Enabled Data Migration Improving speed, efficiency and data quality during PACS migrations AI Enabled Migrations improve the quality of migrations through improving price, speed and quality For personal use only 1 2 3 4 5 DATA EXTRACTION DATA TRANSFORMATION DATA STANDARDIZATION DATA VALIDATION DA
Slide 39: AI Enabled Data Migration
AI Enabled Data Migration Improving speed, efficiency and data quality during PACS migrations STANDARD MIGRATION (6-8 WEEK SETUP PROCESS) For personal use only ORIGINAL STUDY DESCRIPTION MANUAL STANDARDIZED DESCRIPTION All PACS CT C-Spine (x1000) Data (x2500) Cervical CT (x500) CT C-SPINE (x1025) CT
Slide 40: OEM Engagement
OEM Engagement Material interest in combined Ensight and Migration Services offering Migration Services: • Commercial and Contract discussions with 6 OEMs. • Covering >60% PACS market share with committed revenue For personal use only potential. Ensight Prospects: 2024 PACS Market Share Philips Mera